NASDAQ:ABIO opened at $2.35 on Friday. The company’s 50 day moving average price is $2.34 and its 200-day moving average price is $2.21. ARCA biopharma has a 52 week low of $1.71 and a 52 week high of $3.84. The stock has a market cap of $33.86 million, a price-to-earnings ratio of -1.81 and a beta of 2.20.
Several hedge funds have recently made changes to their positions in ABIO. Marquette Asset Management LLC bought a new stake in shares of ARCA biopharma during the 1st quarter valued at $40,000. Millennium Management LLC bought a new stake in shares of ARCA biopharma during the 3rd quarter valued at $47,000. Goldman Sachs Group Inc. bought a new stake in shares of ARCA biopharma during the 2nd quarter valued at $49,000. Virtu Financial LLC bought a new stake in shares of ARCA biopharma during the 1st quarter valued at $55,000. Finally, Dimensional Fund Advisors LP purchased a new position in ARCA biopharma during the fourth quarter valued at $91,000. Hedge funds and other institutional investors own 28.12% of the company’s stock.
ARCA biopharma Company Profile (Get Rating)
ARCA biopharma, Inc, a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.
- Get a free copy of the StockNews.com research report on ARCA biopharma (ABIO)
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.